We’re pleased to keep our customers and future customers up to date with both company and industry news.
Here you will find all our latest news and company announcements along with our thoughts on what’s happening in the world of medical device manufacturing.
Why biocompatibility testing should be considered early in medical device development
By Alastair Fry, Head of Regulatory Affairs at Europlaz When people talk about medical device development, the focus often lands on functionality, usability and clinical performance. Those things matter, of course. But from a regulatory and patient safety perspective,...
Reduce rework and scale-up delays with a free 30-minute manufacturing risk review
Early manufacturing input can help design houses and OEM engineering teams avoid costly issues later in development. In medical device development, small decisions made early can have a big impact later. A tolerance that looks acceptable on paper may create assembly...
Young people aren’t avoiding manufacturing; we’re just not speaking their language
By Katy O’Keeffe, Director, Europlaz Manufacturing has spent years telling itself the same story: there aren’t enough skilled people. Teams are ageing, fewer young people are entering engineering, and businesses are struggling to recruit. After more than twenty years...
UK Contract Medical Device Manufacturers: 2026 Guide
Capabilities, compliance requirements & supplier selection framework Choosing between UK contract medical device manufacturers (CM) is one of the most consequential decisions in bringing a device from design to market. The right partner reduces regulatory risk,...
Europlaz awarded made smarter adoption East of England grant to accelerate digital transformation
Strengthening digital capability through Government-supported investment Europlaz is delighted to announce the successful completion of a significant digital transformation project made possible through the Made Smarter Adoption East of England Programme. The...
Europlaz invests in skills and training to support the future
Europlaz is investing heavily in skills and training to support long term growth and strengthen the UK manufacturing workforce. Here is why this matters now more than ever. Europlaz is investing heavily in the future of its workforce with a 500 percent increase...
Cleanroom Injection Moulding
Cleanroom injection moulding has become essential to the medical, diagnostic and pharmaceutical sectors. As devices become smaller, more complex and more tightly regulated, manufacturers increasingly require production environments that protect components from...
IVDR Manufacturing: How the New Rules Affect Production and Market Readiness
Europe’s transition to the In Vitro Diagnostic Regulation (IVDR) has continued to evolve, especially after the 2024 amendments that introduced longer transition periods for many IVDs. While the sector once worried about steep 2025 deadlines, the updated timelines mean...
Europlaz at Industry Events 2026
In 2026, Europlaz will be visiting leading medtech, pharmaceutical, and advanced manufacturing events across the UK, Europe, and beyond. We’re there to connect with partners, explore emerging technologies, and discuss how our facilities and capabilities can accelerate...
UK medtech trends 2026: Europlaz outlines eight forces reshaping the sector
NHS Net Zero momentum, progressive new NHS initiatives such as NICE's Early Value Assessment (EVA) programme, domestic reshoring, automation at scale, additive manufacturing, AI‑accelerated sourcing, lifecycle compliance, and practical sustainability set the...
NHS Net Zero supplier requirements 2026
The NHS is tightening sustainability expectations across its supply chain, scaling requirements that now touch all new procurements and moving toward product‑level carbon footprinting. Suppliers must evidence board‑approved Carbon Reduction Plans (CRPs), report Scope...
NICE EVA: Early‑use healthtech guidance 2026
NICE’s Early Value Assessment (EVA) has matured into early‑use HealthTech guidance, enabling conditional NHS recommendations for promising technologies that address national unmet needs while real‑world evidence is generated. EVA/early‑use decisions rely on lifecycle...